{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:08:38Z","timestamp":1790791718131,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004012","name":"Jane and Aatos Erkko Fundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004155","name":"Magnus Ehrnrooth Fundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy: Oncology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.omton.2024.200766","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T17:10:13Z","timestamp":1706289013000},"page":"200766","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Low-dose decitabine enhances the efficacy of viral cancer vaccines for immunotherapy"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0287-0048","authenticated-orcid":false,"given":"Salvatore","family":"Russo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Feola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Feodoroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Chiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Antignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manlio","family":"Fusciello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"D\u2019Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Hamdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teijo","family":"Pellinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka","family":"M\u00f6ls\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorella","family":"Tripodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikaela","family":"Gr\u00f6nholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4901-3796","authenticated-orcid":false,"given":"Vincenzo","family":"Cerullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2024.200766_bib1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","article-title":"Optimizing oncolytic virotherapy in cancer treatment","volume":"18","author":"Harrington","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omton.2024.200766_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.844866","article-title":"Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response","volume":"13","author":"Taylor","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2024.200766_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071760","article-title":"MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy","volume":"12","author":"Cornel","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2024.200766_bib4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.18632\/oncotarget.1782","article-title":"Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers","volume":"5","author":"Li","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2024.200766_bib5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00262-008-0582-6","article-title":"Treatment of ovarian cancer cell lines with 5-aza-2\u2032-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules","volume":"58","author":"Adair","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2024.200766_bib6","doi-asserted-by":"crossref","DOI":"10.4161\/onci.22450","article-title":"T-cell suppression mediated by regulatory T\u00a0cells infiltrating hepatic tumors can be overcome by GITRL treatment","volume":"2","author":"Pedroza-Gonzalez","year":"2013","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2024.200766_bib7","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nrg.2016.93","article-title":"Targeting the cancer epigenome for therapy","volume":"17","author":"Jones","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.omton.2024.200766_bib8","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.21037\/tcr.2018.06.24","article-title":"Tumor immunotherapy\u2014the potential of epigenetic drugs to overcome resistance","volume":"7","author":"Grunewald","year":"2018","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.omton.2024.200766_bib9","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41375-018-0070-8","article-title":"Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes","volume":"32","author":"Daver","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2024.200766_bib10","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.18632\/oncotarget.1542","article-title":"Alterations of immune response of non-small cell lung cancer with Azacytidine","volume":"4","author":"Wrangle","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2024.200766_bib11","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.omton.2024.200766_bib12","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00262-016-1868-8","article-title":"DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer","volume":"65","author":"Terracina","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2024.200766_bib13","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2021005487","article-title":"A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2024.200766_bib14","article-title":"Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia","volume":"10","author":"Goswami","year":"2022","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omton.2024.200766_bib15","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1105429","article-title":"Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma","volume":"5","author":"Capasso","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2024.200766_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143408","article-title":"Therapeutic Cancer Vaccination with Immunopeptidomics-Discovered Antigens Confers Protective Antitumor Efficacy","volume":"13","author":"Peltonen","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2024.200766_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.826164","article-title":"Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine","volume":"13","author":"Feola","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2024.200766_bib18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.omto.2021.02.006","article-title":"Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform","volume":"20","author":"Yl\u00f6sm\u00e4ki","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2024.200766_bib19","article-title":"Deregulation of HLA-I in cancer and its central importance for immunotherapy","volume":"9","author":"Hazini","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omton.2024.200766_bib20","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2024.200766_bib21","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1158\/1078-0432.CCR-20-1565","article-title":"Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus","volume":"27","author":"Farrera-Sal","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2024.200766_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108103","article-title":"Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment","volume":"236","author":"Feola","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.omton.2024.200766_bib23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/01.cji.0000436722.46675.4a","article-title":"Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In\u00a0Vivo Behavior and Response to Immunotherapy","volume":"36","author":"Lechner","year":"2013","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omton.2024.200766_bib24","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1073\/pnas.0914879107","article-title":"Peptide vaccines prevent tumor growth by activating T\u00a0cells that respond to native tumor antigens","volume":"107","author":"Jordan","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2024.200766_bib25","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.molcel.2021.01.038","article-title":"DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T\u00a0cells","volume":"81","author":"Loo Yau","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omton.2024.200766_bib26","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1002\/dvdy.21658","article-title":"Epithelial-mesenchymal transition (EMT) is not sufficient for spontaneous murine breast cancer metastasis","volume":"237","author":"Lou","year":"2008","journal-title":"Dev. Dynam."},{"key":"10.1016\/j.omton.2024.200766_bib27","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41375-020-1003-x","article-title":"Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network","volume":"35","author":"Gu","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2024.200766_bib28","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ccr.2011.12.029","article-title":"Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells","volume":"21","author":"Tsai","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2024.200766_bib29","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1158\/1078-0432.CCR-06-2762","article-title":"Effect of cytarabine and decitabine in combination in human leukemic cell lines","volume":"13","author":"Qin","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2024.200766_bib30","article-title":"DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer","volume":"9","author":"Luo","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2024.200766_bib31","doi-asserted-by":"crossref","first-page":"E10981","DOI":"10.1073\/pnas.1712514114","article-title":"Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden","volume":"114","author":"Stone","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2024.200766_bib32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41417-020-0189-4","article-title":"Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy","volume":"28","author":"Feist","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omton.2024.200766_bib33","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","article-title":"Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma","volume":"17","author":"Kaufman","year":"2010","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.omton.2024.200766_bib34","article-title":"Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability","volume":"12","author":"Yu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2024.200766_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.873639","article-title":"Combined treatment with epigenetic agents enhances anti-tumor activity of MAGE-D4 peptide-specific T\u00a0cells by upregulating the MAGE-D4 expression in glioma","volume":"12","author":"Bi","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2024.200766_bib36","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2024.200766_bib37","article-title":"MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer","volume":"9","author":"Wu","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omton.2024.200766_bib38","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ymthe.2020.09.041","article-title":"Oncolytic Virus Therapy with HSV-1 for Hematological Malignancies","volume":"29","author":"Ishino","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2024.200766_bib39","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.1158\/1078-0432.CCR-12-3588","article-title":"DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas","volume":"19","author":"Okemoto","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2024.200766_bib40","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3389\/fgene.2013.00184","article-title":"Exploiting tumor epigenetics to improve oncolytic virotherapy","volume":"4","author":"Forbes","year":"2013","journal-title":"Front. Genet."},{"key":"10.1016\/j.omton.2024.200766_bib41","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.ymthe.2019.04.008","article-title":"Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition","volume":"27","author":"Jennings","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2024.200766_bib42","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.71156","article-title":"A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines","volume":"11","author":"Feola","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.omton.2024.200766_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-42668-7","article-title":"Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors","volume":"14","author":"Chiaro","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2024.200766_bib44","article-title":"Current perspectives on mass spectrometry-based immunopeptidomics: the computational angle to tumor antigen discovery","volume":"11","author":"Zhang","year":"2023","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omton.2024.200766_bib45","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1158\/0008-5472.CAN-05-3020","article-title":"De novo induction of a cancer\/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model","volume":"66","author":"Guo","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2024.200766_bib46","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2016289118","article-title":"Noncanonical immune response to the inhibition of DNA methylation by Staufen1 via stabilization of endogenous retrovirus RNAs","volume":"118","author":"Ku","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2024.200766_bib47","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41587-021-01038-8","article-title":"Identification of tumor antigens with immunopeptidomics","volume":"40","author":"Chong","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omton.2024.200766_bib48","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1002\/cncr.23463","article-title":"Evolution of decitabine development","volume":"112","author":"Jabbour","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.omton.2024.200766_bib49","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3390\/cancers13061383","article-title":"Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2024.200766_bib51","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/2326-6066.CIR-15-0073","article-title":"Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model","volume":"3","author":"Wang","year":"2015","journal-title":"Cancer Immunol. Res."}],"container-title":["Molecular Therapy: Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329924000080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329924000080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T11:58:21Z","timestamp":1726833501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329924000080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2950329924000080"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2024.200766","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose decitabine enhances the efficacy of viral cancer vaccines for immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy: Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2024.200766","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"200766"}}